Inmune Bio, Inc.INMBEarnings & Financial Report
Nasdaq
NextMar 27, 2026
INMB Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.4M
Net Profit
$-6.5M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.24
Inmune Bio, Inc. Q3 2025 Financial Summary
Inmune Bio, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-6.5M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-6.5M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Inmune Bio, Inc. Annual Revenue by Year
Inmune Bio, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $14.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $14.0K |
| 2023 | $155.0K |
| 2022 | $374.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28000 | $14000 | $0 | $0 | $0 | $50000 | $0 | $0 |
| YoY Growth | -71.1% | -63.2% | N/A | N/A | N/A | 257.1% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $57.0M | $46.8M | $52.5M | $52.8M | $39.6M | $37.8M | $37.7M | $33.4M |
| Liabilities | $18.9M | $17.8M | $15.4M | $14.1M | $7.5M | $8.1M | $8.8M | $8.0M |
| Equity | $37.3M | $28.2M | $36.3M | $38.7M | $32.1M | $29.7M | $28.9M | $25.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.4M | $-7.5M | $-7.9M | $-7.0M | $-11.0M | $-6.8M | $-7.4M | $-5.4M |